American Association for Cancer Research
23266066cir200787-sup-251943_2_supp_7044478_qrc6hj.pdf (2.91 MB)

Supplementary Figures from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade

Download (2.91 MB)
journal contribution
posted on 2023-04-04, 01:23 authored by Marie V. Daugan, Margot Revel, Romane Thouenon, Marie-Agnès Dragon-Durey, Tania Robe-Rybkine, Carine Torset, Nicolas S. Merle, Rémi Noé, Virginie Verkarre, Stephane Marie Oudard, Arnaud Mejean, Pierre Validire, Xavier Cathelineau, Rafael Sanchez-Salas, Mathew C. Pickering, Isabelle Cremer, Audrey Mansuet-Lupo, Marco Alifano, Catherine Sautès-Fridman, Diane Damotte, Wolf H. Fridman, Lubka T. Roumenina

Supplementary figures


Centre de Recherche des Cordeliers

GenomIC plateform Cochin Institute



The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth. In this study, we examined the processes by which the master complement regulator factor H (FH) affects clear cell renal cell carcinoma (ccRCC) and lung cancer, two cancers in which complement overactivation predicts poor prognosis. FH was present in two distinct cellular compartments: the membranous (mb-FH) and intracellular (int-FH) compartments. Int-FH resided in lysosomes and colocalized with C3. In ccRCC and lung adenocarcinoma, FH exerted protumoral action through an intracellular, noncanonical mechanism. FH silencing in ccRCC cell lines resulted in decreased proliferation, due to cell-cycle arrest and increased mortality, and this was associated with increased p53 phosphorylation and NFκB translocation to the nucleus. Moreover, the migration of the FH-silenced cells was reduced, likely due to altered morphology. These effects were cell type–specific because no modifications occurred upon CFH silencing in other FH-expressing cells tested: tubular cells (from which ccRCC originates), endothelial cells (human umbilical vein endothelial cells), and squamous cell lung cancer cells. Consistent with this, in ccRCC and lung adenocarcinoma, but not in lung squamous cell carcinoma, int-FH conferred poor prognosis in patient cohorts. Mb-FH performed its canonical function of complement regulation but had no impact on tumor cell phenotype or patient survival. The discovery of intracellular functions for FH redefines the role of the protein in tumor progression and its use as a prognostic biomarker or potential therapeutic target.See article by Daugan et al., p. 891 (36).

Usage metrics

    Cancer Immunology Research



    Ref. manager